Vir Biotechnology Inc

+2.24 (+5.11%)

GSK & Vir Biotechnology Announce Sotrovimab Receives Emergency Use Authorization From The US FDA

Published: 05/26/2021 23:00 GMT
Vir Biotechnology Inc (VIR) - Gsk & Vir Biotechnology Announce Sotrovimab Eua From US FDA for Treatment of Mild-to-moderate Covid-19 in High-risk Adults and Paediatric Patients.
Discussions With Global Regulators Regarding Authorisations in Additional Countries Continue to Advance.
Sotrovimab Will Be Available for Appropriate Patients Diagnosed With Covid-19 in the U.S. in the Coming Weeks.
Gsk and Vir Plan to Submit a Biologics License Application (bla) to the FDA in the Second Half of 2021.